AbstractHIVViral Hepatitis and Liver DiseaseHIV-1 Integrase Resistance Associated Mutations and the Use of Dolutegravir in Sub- Saharan Africa: A Systematic Review and Meta-AnalysisView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseHIV transmission clusters in Europe: A perspective view of Late presenters and Non-Late presentersView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseCharacterization of SARS-CoV-2 epidemic and transmission dynamics in children over the four COVID-19 wavesView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseCirculation of sars-cov-2 variants in central Italy: spike variability characterization by deep-sequencingView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseSARS-CoV-2 mutations and variants may muddle the sensitivity of COVID-19 diagnostic assaysView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseImpact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodiesView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseLevels and durability of humoral and T-specific responses after the booster dose of mRNA BNT162b2 vaccine in residents of a Long Term Care FacilityView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseTransmitted drug resistance to integrase based first-line treatment in Europe, 2018-2021View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseHIV-1 Transmitted drug resistance and transmission clusters in newly diagnosed patients in Portugal between 2014 and 2019View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseReaching the 95-95-95 targets will not eliminate HIV transmission in 2030 among individuals born in sub-Saharan Africa residing in the NetherlandsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseHIV reservoir quantification by combining total HIV-1 DNA assay and intact proviral DNA assay (IPDA) in one triplex digital PCR reactionView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseTemporal trend of drug- resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individualsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseComparison of Markers of Inflammation and Associated Baseline Variables in Virologically Suppressed Participants in the TANGO Study at Week 144View Abstract
AbstractHIVViral Hepatitis and Liver DiseasePredictors of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settingsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseAnalysis of mutational history of multi-drug resistant genotypes with a mutagenetic tree modelView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseChanges in the HIV-1 3'- polypurine tract in patients failing dolutegravir in BrazilView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseUsing social media to improve follow-up and routine checks on newly diagnosed young people living with HIV and their adherence to Antiretroviral TherapyView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseResistance analysis of pre- treatment NS3 and NS5A variants in HCV genotype 1a, 1b and 3a infected patients in CroatiaView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEvaluation of the virological efficacy of switching to dolutegravir-based tritherapy in patients followed under real-life conditions in Abidjan, Côte d'IvoireView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseMajor protease resistance in West African HIV-1 subtypes is associated with novel protease mutations and accelerated gag evolution during second-line ARTView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInterpretation of the T66I and G118R mutations in integrase in HIV-2View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseVirological characterization of treatment failures and retreatment outcomes in patients infected with “unusual” HCV genotype 1 subtypesView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseThe acquisition of positively charged amino acids in HBsAg C- terminus impairs HBsAg secretion, affects its structural stability and is associated with HBV-induced liver cancerView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseHBcrAg tightly correlates with elevated HDV replicative activity and with enhanced liver inflammation and damage: role of HBcrAg as a biomarker of liver disease progression in the setting of HDV co-infectionView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseDelayed viral load decrease of Omicron variant compared to Delta variant in 2 nasopharyngeal samples from COVID-19 patients.View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEpidemiological distribution of SARS-CoV-2 lineages by spike region genomic analysis: January 2021-January 2022 variants distribution in Tuscany Nord- Ovest areaView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseA case of re-infection with a different SARS-CoV-2 lineage in an unvaccinated childView Abstract
AbstractHIVViral Hepatitis and Liver Disease26 Study on the continuity of Tuberculosis (TB) care services in a COVID-19 context, Senegal, 2021View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseSituation with COVID-19 among HIV-infected patients in ArmeniaView Abstract
AbstractHIVViral Hepatitis and Liver Disease28 Study on the continuity of HIV care services in a COVID-19 context, Senegal, 2021View Abstract
AbstractHIVViral Hepatitis and Liver DiseasePrevalence of coranavirus disease-2019(COVID-19) in a testing centre in Anambra state, NigeriaView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Transmission Clusters of Acute Hepatitis C Virus Among Men Who Have Sex With Men in the Netherlands. A phylogenetic analysis.View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEpidemiological and clinical features of SARS-CoV-2 variants circulating between April- December 2021 in ItalyView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseHIV-1 Molecular Phylogenies Characterized by Near Full- Length Genome SequencingView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseGenome characterization of HIV- 2 biological clones isolated from long term non-progressors (LTNP) vs patients with progressive infectionView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEpidemiology of HIV -1 recombinant 2010-2018. forms in IsraelView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseIdentification of a New HIV-1 Circulating Recombinant Form CRF91_cpx in CyprusView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseHepatitis B Virus Sub-genotype A1 Evolutionary Dynamics in BotswanaView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseThe evaluation of a 5-plex “rainbow” digital PCR assays to measure intact HIV-1 proviral DNAView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePatterns of PrEP use among first- time users of oral HIV pre- exposure prophylaxis in the general population in EswatiniView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseQuality of life of injecting drug users living with HIV in Minsk, BelarusView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEvolutionary dynamics of the recently identified HIV subtype a outbreak in Montenegro explored through advanced phylodynamic approachView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseUpdate on transmitted drug resistance in newly diagnosed HIV patients during the period from 2019 to 2020View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseArchived HIV-1 drug resistance is driven by NNRTI-mutations and associated with viral replication among adolescents in CameroonView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseIncreasing protease inhibitor resistance mutations among HIV-infected children and adolescents with virologic failureView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseDetection of mutations associated with antiretroviral drug resistance from HIV proviral DNA in patients with low-level viremiasView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseClonal Case Assessments for Participants Failing with Emergent Integrase Resistance in the DAWNING Second Line StudyView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseK156N integrase substitution in combination with 3’PPT resistance mutations against dolutegravirView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseLong-term Efficacy, Safety, and Durability of Ibalizumab-based Regimens in Subgroup of TMB- 202 ParticipantsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseResidual HIV-1 RNA in 4d on/3d off (ANRS 170 QUATUOR) through W96View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseSwitch to ART with BIC/FTC/TAF achieves virological control in patients with low level viremiaView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseImplementation of HCV- infection treatment programm with DAA in armenia among HIV- infected patients in COVID-19 eraView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseImpacts of Differentiated Service Delivery Model (DSDM) on Adherence (ADH) to clinical appointment Among Children and Adolescent Living with HIV (CALHIV) attending at Mbeya Center of Excellence (COE), Baylor-TanzaniaView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseHIV and SARS-CoV-2: the interplay of two wicked problemsView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePrevalence and viral load suppression rate among children and adolescents with dual infections (any two of HIV, HBV, and HCV) in Nnewi, NigeriaView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseProviral DNA for detection of HIV-1 subtype A drug resistance mutationsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseCombined COVID-19 vaccination and hepatitis C virus screening intervention for high-risk populations at a centre for addiction services in Barcelona, SpainView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseCombined COVID-19 vaccination and hepatitis C virus and HIV screening intervention for high- risk populations at a mobile testing unit in Madrid, SpainView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseCommunity perspectives on self- testing for HIV and HCV in the WHO European regionView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseViral load suppression after three-year Ibalizumab treatment in a multidrug-resistant HIV-1- infected woman: Clinical experience.View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseCASE - HIV+ End-Stage Renal Disease Patient with Immunosuppressive Drug-Drug Interactions Received Successful Transplantation after Ibalizumab Suppressed SwitchView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseClinical course of AIDS with COVID-19 coinfection with prolonged SARS CoV-2 replication despite remdesivir/molnupiravir treatment.View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseA Case of IRIS Syphilis Due to Prozone EffectView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseSeroprevalence of SARS-CoV-2 infection and evolution of humoral immune response in PLWHIV in the Ile-de-France areaView Abstract
